---
audienceLevel: patient
cancerTypes:
- bladder
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Nogapendekin Alfa Inbakicept-pmln - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/nogapendekin-alfa-inbakicept-pmln
version: v1
---

# Nogapendekin Alfa Inbakicept-pmln - NCI

# Nogapendekin Alfa Inbakicept-pmln

Placeholder slot

(noh-GAP-en-DEH-kin AL-fuh in-BAK-ih-sept)

This page contains brief information about nogapendekin alfa inbakicept-pmln
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Anktiva

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eae31db8-3e7a-d9e0-708d-74419d1b50ff&audience=consumer)

## Use in Cancer

Nogapendekin
alfa inbakicept-pmln is approved to treat:

- **[Non-muscle–invasive bladder cancer](/Common/PopUps/popDefinition.aspx?id=45122&version=Patient&language=English)** with [carcinoma in situ](/Common/PopUps/popDefinition.aspx?id=46488&version=Patient&language=English), with or without [papillary tumors](/Common/PopUps/popDefinition.aspx?id=46240&version=Patient&language=English). It is used with [bacillus Calmette-Guérin](/Common/PopUps/popDefinition.aspx?id=44581&version=Patient&language=English) (BCG) in adults whose cancer does not respond to treatment with BCG alone.

Nogapendekin
alfa inbakicept-pmln
is also being studied in the treatment of other types of
cancer.

## More About Nogapendekin Alfa Inbakicept-pmln

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/751380) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Nogapendekin
Alfa Inbakicept-pmln](https://medlineplus.gov/druginfo/meds/a624034.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Immunotherapy For Cancer](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Nogapendekin Alfa Inbakicept-pmln](https://www.cancer.gov/research/participate/clinical-trials/intervention/C205507) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
